Featured GeneDx blog posts

New research presented at the Medicaid Health Plans of America Annual Conference found that, among children with developmental delay, intellectual disability, and epilepsy who underwent stepwise genetic testing, prior testing added an average of 19 months and $2,039 in genetic testing costs before exome or genome sequencing (ES/GS). In a budget impact analysis of 5,821 children covered by Medicaid, a first-tier ES/GS approach was associated with an estimated $294 in savings per patient per year over five years. Some Medicaid plans have already updated their coverage policies in response to evidence and professional society guidance. These findings support continued modernization among the remaining plans that still require prior testing, with the potential to reduce unnecessary testing, shorten time to diagnosis, and improve long-term budget performance. 

Diagnosis Drives Action is a GeneDx initiative elevating the voices of patients, families, clinicians, and advocacy organizations to show how a genetic diagnosis can create a path forward—from informed care and community connection to research opportunities and hope.

When unexpected findings during pregnancy led to a NICU stay, rapid genome sequencing gave Cayden’s family an answer within days. His diagnosis helped them begin specialist care, early intervention, and care planning without a prolonged diagnostic journey.